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PHEOCHROMOCYTOMAS ANDparagangliomas are chromaf-fin cell tumors of neural crestorigin that arise from the
adrenal medulla or extra-adrenal sym-
pathetic paraganglia, respectively, and
are frequently catecholamine secret-
ing.1 These tumors are usually benign
and can occur as a single entity or as
part of various hereditary tumor syn-
dromes. Genetically, pheochromocy-
tomas and paragangliomas are hetero-
geneous, with at least one-third of
cases resulting from germline but not
somatic mutations in 1 of several
independent genes: RET, VHL, NF1,
and succinate dehydrogenase (SDH)
subunit B, C, and D genes.2-5 More
recently, other candidate susceptibil-
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Context Pheochromocytomas and paragangliomas are genetically heterogeneous neu-
ral crest–derived neoplasms. We recently identified germline mutations of the novel
transmembrane-encoding gene FP/TMEM127 in familial and sporadic pheochromo-
cytomas consistent with a tumor suppressor effect.
Objectives To examine the prevalence and spectrum of FP/TMEM127 mutations
in pheochromocytomas and paragangliomas and to test the effect of mutations in vitro.
Design, Setting, and Participants We sequenced the FP/TMEM127 gene in 990
individuals with pheochromocytomas and/or paragangliomas, including 898 previ-
ously unreported cases without mutations in other susceptibility genes from 8 inde-
pendent worldwide referral centers between January 2009 and June 2010. A multi-
plex polymerase chain reaction–based method was developed to screen for large gene
deletions in 545 of these samples. Confocal microscopy of 5 transfected mutant pro-
teins was used to determine their subcellular localization.
Main Outcome Measures The frequency and type of FP/TMEM127 mutation or
deletion was assessed and correlated with clinical variables; the subcellular localization
of 5 overexpressed mutants was compared with wild-type FP/TMEM127 protein.
Results We identified 19 potentially pathogenic FP/TMEM127 germline mutations
in 20 independent families, but no large deletions were detected. All mutation carriers
had adrenal tumors, including 7 bilateral (P=2.710−4) and/or with familial disease
(5 of 20 samples; P=.005). The median age at disease onset in the FP/TMEM127 mu-
tation group was similar to that of patients without a mutation (41.5 vs 45 years, re-
spectively; P=.54). The most common presentation was that of a single benign ad-
renal tumor in patients older than 40 years. Malignancy was seen in 1 mutation carrier
(5%). Expression of 5 novel FP/TMEM127 mutations in cell lines revealed diffuse lo-
calization of the mutant proteins in contrast with the discrete multiorganelle distribu-
tion of wild-type TMEM127.
Conclusions Germline mutations of FP/TMEM127 were associated with pheochro-
mocytoma but not paraganglioma and occured in an age group frequently excluded
from genetic screening algorithms. Disease-associated mutations disrupt intracellular
distribution of the FP/TMEM127 protein.
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ity genes have also been reported,
including KIF1Bβ,6,7 EgIN1/PHD2,8
SDHAF2,9,10 and SDHA,11 although
these findings remain restricted to 1
or 2 occurrences of the reported
mutations. Despite this broad spec-
trum of susceptibility genes, the
molecular basis for the majority of
pheochromocytomas and paraganglio-
mas, including most of the sporadic
and rare familial cases, remains
unknown. These observations support
the existence of additional pheochro-
mocytoma susceptibility genes, which
may account for some of the geneti-
cally undefined cases.12,13
We recently identified TMEM12714
(NM_017849.3) as the pathogenic tar-
get of the familial pheochromocytoma
(FP) locus, which we previously mapped
to chromosome 2q11.13 Germline
FP/TMEM127 mutations were found
both in familial and sporadic-appear-
ing pheochromocytomas, with loss of
the wild-type allele in tumor DNA con-
sistent with its role as a tumor suppres-
sor gene. FP/TMEM127 encodes a highly
conserved 3-spanner transmembrane
protein that localizes to multiple intra-
cellular organelles and is linked to regu-
lation of the mTORC1 signaling com-
plex, a critical control node for protein
synthesis and cell survival.14 All but 1
of the 7 initially discovered mutations
were truncating and resulted in mark-
edly reduced expression of the
FP/TMEM127 gene in the evaluable tu-
mors, suggesting that the mutations re-
sult in loss of FP/TMEM127 function in
the tumor tissue.
In recent years, specific genotype-
phenotype associations in pheochromo-
cytomas due to mutations in the vari-
ous susceptibilitygeneshavespurred the
development of guidelines for genetic
screening of these patients, with a goal
of improving the outcomes of affected
and at-risk individuals.3,5,15,16 To define
the prevalence and genotype-pheno-
type correlations in FP/TMEM127-
mutated cases, we sequenced the
FP/TMEM127gene in 990 pheochromo-
cytoma and paraganglioma patients and
examined545of these samples forgerm-
line deletions of the gene. We also deter-
mined the subcellular localization of 5
novel mutations by in vitro confocal
microscopy.
METHODS
Patients
A total of 990 samples from patients with
pheochromocytomas and paraganglio-
mas without mutations in RET, VHL,
SDHB, SDHC, and SDHD and who had
no clinical features of neurofibromato-
sis type 1 were studied. In addition, 319
of these samples were negative for
SDHAF2 and 52 forKIF1Bβ gene muta-
tions. A cohort of 898 samples were re-
cruited from a multi-institutional col-
laborative effort derived from the
International Familial Pheochromocy-
toma Consortium, which encompassed
referral centers based in the United States
(San Antonio, Texas, and Ann Arbor,
Michigan), Italy (Padova, Florence, and
Brescia), Spain (Madrid), England (Bir-
mingham and London), Brazil (Sa˜o
Paulo), Belgium (Brussels), and Argen-
tina (Buenos Aires). Written informed
consent was obtained from patients in ac-
cordance with institutional review
board–approved protocols from each
center. Eighteen samples were ob-
tained from the Cancer Therapy and Re-
search Center Pathology Tumor Bank at
the University of Texas Health Science
Center at San Antonio. Diagnosis of
pheochromocytoma and/or paragan-
glioma, including tumors of both sym-
pathetic (thoracic or abdominal) and
parasympathetic (head and neck) ori-
gin, was established following conven-
tionalprocedures (includingclinical, bio-
chemical, and imaging tests) and the
diagnosis was confirmed histologically
in every case. Tumors were considered
familial when more than 1 affected in-
dividual was identified in the family. The
study was performed between January
2009 and June 2010.
We previously reportedFP/TMEM127
sequence variations in a cohort of 103
patients with pheochromocytoma and/or
paraganglioma.14 In the present study, 92
of these cases were used for genotype-
phenotype associations with the 898 new
cases described above. Eleven cases from
the original cohort that had germline mu-
tations in other known pheochromocy-
toma susceptibility genes were ex-
cluded.14 The main features of each series
of theentire cohort are shown inTABLE1.
DNA Isolation
Of the new series of 898 samples, DNA
was isolated from blood in 774 cases
and from tumor tissue in 124 cases, fol-
lowing standard procedures.14
Control Population
A control group composed of samples of
Europeans, South Americans (heteroge-
neous population mainly of Latino ori-
gin but also including non-Hispanic
whites, Asians, African Americans, and
indigenous Native Americans), North
Americans (including both Hispanic and
non-Hispanic whites and African Ameri-
cans), and Asians totaling 1064 alleles
was used as reference samples, as re-
ported.14 In addition to these, 718 new
alleles were screened for exon 3 of the
FP/TMEM127 gene only. This group
comprised 318 alleles of white ancestry
and 404 alleles of South American ori-
gin similar in racial/ethnic composition
to those described above.
Polymerase Chain Reaction
and Direct Sequencing
TodefinetheprevalenceofFP/TMEM127
mutationinalarge,multi-institutionalco-
hortofpheochromocytomasandparagan-
gliomas,all4exonsofFP/TMEM127were
amplified by polymerase chain reaction
(PCR) and directly sequenced as previ-
ously reported.14 Primer sequences
are listed in eTable 1 (available at http:
//www.jama.com).
The accession numbers for nucleo-
tides (NM_017849.3) and respective
protein variations (NP_060319.1) de-
tected in this study were deposited in
the National Center for Biotechnology
Information (NCBI) single-nucleotide
polymorphism (SNP) database (http:
//www.ncbi.nlm.nih.gov/SNP/tranSNP
/VarBatchSub.cgi).
Pathogenic Mutation Call
Variations that included nonsynony-
mous sequence substitutions, inser-
tions, deletions, duplications, or splice
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site or nonsense changes and that were
absent in the control group were con-
sidered potentially pathogenic in the
present analysis. Synonymous substi-
tutions, variants affecting intronic re-
gions not immediately adjacent to the
intron-exon border, or changes de-
tected in the control group or in the
SNP database (dbSNP, NCBI) were not
considered of pathogenic relevance for
the purposes of this study. We also used
3 prediction software modules to evalu-
ate the pathogenic potential of
the identified variants. Two of them,
PolyPhen-2 (http://genetics.bwh
.harvard.edu/pph2/)17 and SIFT (http:
//sift.jcvi.org/),18 are algorithms that pre-
dict the possible effect of an amino acid
substitution on the structure and func-
tion of a human protein based on physi-
cal/structural considerations (eg, amino
acid properties) and sequence homol-
ogy. The third program, NetStart 1.0,
predicts initiation of translation sites in
eukaryotes based on a training data
set of mRNA derived from genomic
sequences with known start sites
(http://www.cbs.dtu.dk/services
/NetStart/).19
Quantitative Multiplex PCR
of Short Fluorescent Fragments
To assess larger deletions that might dis-
rupt the FP/TMEM127 gene and that
would not be detected by direct se-
quencing, a quantitative multiplex PCR
of short fluorescent fragments method
was designed. The assay comprised 6
sets of primers spanning the 5 UTR,
exons 1 through 4, and 3 UTR of the
FP/TMEM127 gene (eTable 1). Each
forward primer was labeled with a
6-FAM-5 fluorescent tag, and frag-
ments were amplified in a multiplex
PCR as previously described.20 In ad-
dition, amplicons spanning distinct
chromosomal regions (chromosomes 1,
11, or 17) were included in the multi-
plex reaction as internal controls. Two
to 3 normal DNA samples were run
within each batch to serve as refer-
ences for normal, 2-copy gene pat-
tern. A total of 545 germline samples
with high-quality, high-molecular-
weight DNA were successfully pro-
cessed through this assay. Results were
analyzed using Peak Scanner soft-
ware, version 1.0 (Applied Biosys-
tems, Foster City, California) as previ-
ously reported.20 Reliability of the assay
was validated by the detection of mono-
allelicFP/TMEM127 loss in tumor DNA
from previously reported mutant
samples, which were known to carry
loss of the wild-type TMEM127 al-
lele14 and, thus, represented models of
single-copyTMEM127 loss (eFigure 1).
Loss of Heterozygosity Analysis
Loss of heterozygosity (LOH) analysis
is a classic method to test whether a
gene involved in tumor susceptibility
has features of a tumor suppressor gene.
In classic tumor suppressor genes, LOH
consists of loss of the wild-type allele
in tumor DNA, or the “second hit” (the
first hit being the germline mutation in
hereditary tumors), which results in loss
of functional copies of the putative tu-
mor suppressor gene in the tumor tis-
sue. To identify the second hit of FP/
TMEM127 inactivation in samples
carrying a mutation, LOH analysis was
performed in 4 cases in which tumor
DNA was available. Loss of heterozy-
gosity was identified when the wild-
type–mutant allele ratio was less than
0.5 based on sequence data from germ-
line and tumor DNA, as described.14
Loss of heterozygosity data were avail-
able from 6 previously reported
samples.14
RNA and Reverse
Transcription–PCR Analysis
To demonstrate the effect of the
c.4091GT mutation on splicing of
the TMEM127 transcript, RNA was ob-
tained from peripheral lymphocytes of
the patient carrying this mutation.
Complementary DNA was prepared by
reverse transcription using standard
procedures14 and used for a PCR span-
ning nucleotides 180 to 677 of the
FP/TMEM127 open reading frame
(primer sequences listed in eTable 1),
followed by direct sequencing of the
products.
Table 1. Summary of Clinical Features of the Entire Pheochromocytoma and Paraganglioma Cohort by Original Study Sites and Previously
Reported Samples
United
States
(n = 176)
Spain
(n = 168)
Padua,
Italy
(n = 200)
Florence,
Italy
(n = 106)
Brescia,
Italy
(n = 52)
Belgium
(n = 67)
Brazil
(n = 52)
United
Kingdom
(n = 77)
Qin et al,14
2010
(n = 92)
Total
(N = 990)
Age at diagnosis, mean
(range), y
46.3
(7-78)
47.0
(11-80)
47.1
(5-79)
44.1
(9-80)
52.1
(20-83)
48
(12-84)
39.3
(7-74)
25.5
(5-65)
41.1
(4-76)
43.3
(4-84)
Sex, No.
Female 107 94 104 58 27 46 32 51 60 579
Male 63 65 96 48 25 21 20 26 32 396
Unknown 6 9 0 0 0 0 0 0 0 15
Tumor location, No.
Total adrenal 144 133 190 80 42 37 43 52 76 798
Bilateral adrenal 7 11 15 6 1 1 1 15 8 65
Total extra-adrenal 32 35 10 26 10 30 9 21 16 189
Extra-adrenal head and neck 3 17 0 0 8 25 1 4 2 60
Adrenal and extra-adrenala 2 4 1 1 0 0 0 0 0 8
Unknown 0 0 0 0 0 0 0 4 0 4
Malignancy, No. 12 4 13 3 3 4 5 4 4 52
Familial history, No. 5 4 6 0 1 1 2 0 12 31
aAdrenal and extra-adrenal samples are included in the total adrenal samples.
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Constructs, Transfections,
and Confocal Microscopy
To begin to determine the effects of
FP/TMEM127mutations invitro,wegen-
erated clones carrying 5 novel substitu-
tion mutations identified in the present
series.Fourof themutations(c.280CT,
p.Arg94Trp; c.208GA, p.Asp70Asn;
c .419GA, p.Cys140Tyr; and
c.418TC,p.Cys140Arg)wereobtained
using site-directed mutagenesis (Phu-
sion,NewEnglandBiolabs, Ipswich,Mas-
sachusetts)fromwild-typeFP/TMEM127
sequence cloned intoHindIII/EcoRI sites
of the pEGFP-C2 vector (Clontech,
Mountain View, California), as previ-
ously described.14 Additionally, the
c.3GT (p.Met1?) mutation was gen-
erated by PCR, using as the start codon
an in-frame methionine at position 85
and cloned as above. All constructs were
verified by sequencing. The remaining
constructs that led to truncating prod-
uctshadpreviously showntobeunstable
for protein detection.14 Each construct,
as well as the wild-type version, was
transfected into HEK293T, HeLa, or
MPC9/30 (mouse pheochromocytoma
cell line21)cells.After24hours,cellswere
fixed and imaged by confocal micros-
copyaspreviouslyreported.14 Greenfluo-
rescent protein (GFP) fluorescence of
transfected cells was examined for sub-
cellular localization as punctate (wild-
type) or diffuse patterns.
Statistical Analysis
Statistical analyses were carried out
using SPSS software, version 17.0 (SPSS
Figure 1. Pathogenic FP/TMEM127 Gene Mutations Identified in Pheochromocytomas
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Inc, Chicago, Illinois). Because
FP/TMEM127 mutations were de-
tected exclusively in patients with pheo-
chromocytoma, only this group was
used for statistical studies. Differ-
ences between pheochromocytoma mu-
tation carriers and non–mutation car-
riers were assessed for sex, bilaterality,
familial history, and malignancy using
a 2 test or the Fisher exact test when
appropriate. The Mann-Whitney test
was applied for testing age differ-
ences. Nominal 2-sidedP.05 was con-
sidered statistically significant. A modi-
fied Bonferroni-corrected nominal
threshold of P=.05/N*was used to cor-
rect for multiple hypothesis testing
where N* is the number of indepen-
dent comparisons. We further evalu-
ated age at disease onset of the current
series in comparison with 2 previ-
Table 2. Genetic and Clinical Features of the 20 Probands With FP/TMEM127 Mutations Considered Likely to be Pathogenica
Mutationb
Sex/
Age, yc
Tumor
Location
Malignancy
Status
Family
History
Other
Disease LOH
Predicted
Truncation
or Aberrantly
Sized
Proteind
Predicted
Pathogenicitye
Total
Samples/
Total
Adrenal
Tumorsf
No. of
Mutation
Samples
% of Total
Samples
Wth
Mutations/
Adrenal
% of Tumor
Samples
Wth
Mutationsg
United States 176/144 3 1.70/2.08
c.280CT, p.Arg94Trp F/43 A B N ND N Y
c.208GA, p.Asp70Asn F/50 A B N Y N Y
c.3GT, p.Met1? F/61 A B N Acrocyanosis Y Y Y
Padua, Italy 200/190 5 2.50/2.63
c.217GC, p.Gly73Arg M/44 A B N ND N Y
c.76CT, p.Gln26X F/37 A B N ND Y ND
c.447GA, p.Trp149X F/40 A(Bi) B N ND Y ND
c.158GC, p.Trp53Ser M/21 A B N Bone marrow
failure
Y N Y
c.419GA, p. Cys140Tyr F/59 A(Bi) M N Diffuse
metastases
ND N Y
Spain 168/133 1 0.60/0.75
c.409  1GT,
r.245_409del
(p.Asp82_Thr136del)
F/38 A B Y Breast cancer ND Y ND
Florence, Italy 106/80 1 0.94/1.25
c.627_640dupGCTGCT
CTCAGAGA,
p.Met214Serfs98X
F/26 A(Bi) B N Papillary
thyroid
carcinoma,
medullary
thyroid
hyperplasia
ND Y ND
United Kingdom 77/52 1 1.30/1.92
c.-18CT, p.? M/44 A B N ND Y Y
Brazil 52/43 1 1.92/2.32
c.116_119delTGTC,
p.Ile41ArgfsX39
F/34 A B N Macrovascular
disease
ND Y ND
Belgium 67/37 1 1.49/2.70
c.418TC, p.Cys140Arg F/47 A B N ND N Y
Qin et al,14 2010 92/76 7 7.61/9.21
c.410-2AC, r.410_417del
(p.Leu138CysfsX12)
F/34 A(Bi) B Y Y Y ND
c.149_150insA,
p.Pro51ThrfsX57
F/25 A B U Y Y ND
c.475CT, p.Gln159X F/72 A(Bi) B Y Y Y ND
c.265_268delACAG,
p.Thr89fsX35
M/46 A(Bi) B N Y Y ND
c.410-2AC, r.410_417del
(p.Leu138CysfsX12)
F/37 A B Y Y Y ND
c.245-1GT, r.245_264del
(p.Phe83SerfsX18)
F/66 A(Bi) B Y Y Y ND
c.268GA, p.Val90Met F/32 A B N ND N Y
Abbreviations: A, adrenal; B, benign; Bi, bilateral; LOH, loss of heterozygosity; M, malignant; ND, not done; U, unknown (adopted); Uni, unilateral.
aOnly data from probands are shown in the table.
bNucleotide and protein nomenclature according to Human Genome Variation Society.
cSummary mean age, 42.8 years.
dPredicted changes that affect protein size or frame are considered truncating mutations; others are missense variants.
ePathogenicity potential of missense variants was examined by PolyPhen2, SIFT, and NetStart 1.0 software.
fOnly study groups in which a mutation was found are shown; the total number of tested samples is 990.
gTotal frequency of FP/TMEM127 mutations does not include the 92 samples previously reported because they are biased by the presence of familial pheochromocytoma–linked
samples.14 Summary mean frequency of mutations is 1.89%.
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ously published pheochromocytoma/
paraganglioma cohorts (the Spanish
series4 and the Italian series5). A pro-
portions-difference test for 2 indepen-
dent samples was applied to deter-
mine the degree of heterogeneity
between these series. This test showed
that the cohorts were not heteroge-
neous and, thus, could be combined for
the comparative analysis.
RESULTS
A total of 44 distinctFP/TMEM127 vari-
ants were detected in 990 samples from
pheochromocytoma or paragan-
glioma patients (FIGURE 1,TABLE 2, and
eTable 2). Of these, 19 mutations found
in 20 patients were considered of po-
tential pathogenic significance (2.02%)
(Table 2). Thirteen of these variants
were novel changes, while the remain-
der had been previously reported.14 Ap-
proximately half of the mutations (10/
19) comprised small deletions,
duplications, or nonsense or splice site
substitutions that led to truncation or
extension (1 mutation) of the pre-
dicted FP/TMEM127 product. The
other 9 variants were nonsynonymous
missense mutations affecting con-
served codons of the FP/TMEM127 se-
quence (Table 2). None of these 19 se-
quence variants was detected in an
ethnically matched control group com-
prising 1064 alleles (or, in the case of
exon 3, 718 additional alleles). The con-
stitutive (germline) nature of the mu-
tation could be determined in all but 1
case in which only somatic tissue was
available for the analysis (c.208GA,
p.Asp70Asn) (eFigure 1A). Loss of het-
erozygosity of the wild-type allele was
detected in 4 new cases in which tumor
DNA was available (Table 2 and eFigure
1A). None of the 545 germline samples
analyzed for larger FP/TMEM127 dele-
tions showed evidence of partial or
complete deletion of the gene.
The mutations spanned all 3 coding
exons of FP/TMEM127 (Figure 1), and
13 of them affected 1 or more trans-
membrane domains of the predicted
protein (Figure 1, Table 2, and eFig-
ure 2), highlighting the relevance of
these domains for FP/TMEM127 func-
Table 3. Relative Frequency of FP/TMEM127 Mutation in Patients With Single Adrenal
Tumor Presentation Without Family History (Truly Sporadic Samples) vs Other
Pheochromocytoma Susceptibility Genes, by Age Group
Mutated Gene
No. of
Mutations/Total
Cases (%)a
No. of
Mutations/Cases
Aged 40 y (%)
No. of
Mutations/Cases
Aged 45 y (%)
Current series
TMEM127 11/547 (2.01) 6/335 (1.8) 3/269 (1.1)
Spanish series4
VHL 2/95 (2.1) 0 0
RET 0 0 0
SDHB 2/95 (2.1) 1/66 (1.52) 1/51 (1.96)
SDHC 0 0 0
SDHD 0 0 0
Italian series5
VHL 6/233 (2.57) 0 0
RET 2/233 (0.86) 0 0
SDHB 3/233 (1.29) 0 0
SDHC 0 0 0
SDHD 3/233 (1.29) 1/157 (0.6) 1/141 (0.71)
Combined series4,5
VHL 8/328 (2.43) 0 0
RET 2/328 (0.60) 0 0
SDHB 5/328 (1.52) 1/223 (0.44) 1/192 (0.52)
SDHC 0 0 0
SDHD 3/328 (0.91) 1/223 (0.44) 1/192 (0.52)
aNumbers of mutations and total cases included only unilateral adrenal tumors without family history for the 3 cohorts
examined.
Figure2.Age-RelatedDistributionofPatientsandAffectedRelativesCarryingFP/TMEM127Mutations
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Dotted line represents mean age at onset (42.8 years). Mutations from families with a single affected individual are
indicated by open circles. Families with more than 1 affected individual (c.245-1GT, c.475CT, c.410-2AC, and
c.410-2AC) are color-coded. The latter 2 are unrelated families with an identical FP/TMEM127 mutation.
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tion. All of the missense mutations were
considered to be potentially patho-
genic by at least 1 of the 3 prediction
programs used to preliminarily evalu-
ate the likelihood of pathogenicity of
the novel missense variants (Table 2 and
eFigure 2) and/or by in vitro assays, as
described herein.
Next, we examined the association of
FP/TMEM127 mutations with various
clinical variables, including age at on-
set, tumor location, and familial history
of pheochromocytoma. The mean age at
development of FP/TMEM127-mutated
tumors was 42.8 years (95% confi-
dence interval [CI], 36.44-49.25 years)
and the median was 41.5 years. This age
at onset is similar to the mean age of non-
mutated cases in this series, 43.2 years
(95% CI, 41.88-44.52 years) (median, 45
years) and to the reported average diag-
nostic age for sporadic pheochromocy-
tomas (47.01 years; 95% CI, 45.42-48.6
years).4,5 This is in contrast with pa-
tients with hereditary pheochromocy-
tomas due to mutations in other suscep-
tibility genes, in whom the disease has
an earlier manifestation (eTable 3). The
single exception are individuals withRET
mutations (eTable 3), who can usually
be distinguished by their unique clini-
cal presentation.2,4,5
Furthermore, FP/TMEM127 muta-
tion frequency in patients presenting
with unilateral pheochromocytomas
without a family history or other syn-
dromic features (11/547 cases [2%])—
ie, truly sporadic-appearing cases—is
similar to that reported for mutations
of theVHL and SDHB genes and higher
than that described for other pheochro-
mocytoma susceptibi l i ty genes
(TABLE 3).4,5 In the group diagnosed af-
ter age 45 years, FP/TMEM127 showed
the highest frequency of mutations
(1.1%) compared with all other sus-
ceptibility genes (Table 3). When all 20
probands and other affected members
from 4 different families were com-
bined (n=29), the age at diagnosis of
pheochromocytoma was older than 40
years in two-thirds of these individu-
als and older than 50 years in almost
one-third of the cases (FIGURE 2). In a
single family in which multiple af-
fected individuals were available for
analysis, 7 of 11 individuals carrying the
c.410-2AC mutation had clinical dis-
ease by age 55 years, while 1 mutation
carrier remained free of disease at age
60 years.14
All mutated tumors arose from the
adrenal medulla. No mutations were
detected among the 189 extra-adrenal
tumors, including 60 head and neck
paragangliomas. Overall, one-third
of patients with a mutation had bilat-
eral tumors (7/20; P = 2.7 10−4).
FP/TMEM127mutations were detected
in 11% (7/65) of all bilateral pheochro-
mocytomaswithoutothergenetic cause.
None of the 9 bilateral cases diagnosed
in the pediatric group (younger than 20
years) had an FP/TMEM127 mutation.
A clear family history of pheochromo-
cytoma was present in only a quarter
of patients carrying a mutation (5/20;
P=.005).
Most tumors with an FP/TMEM17
mutation were benign. However,
1 patient carrying a missense muta-
tion (c.419GA, p.Cys140Tyr) had
multiple vertebral metastases. In
another patient (c.116_119delTGTC,
p.Ile41ArgfsX39), features of a more
aggressive histological profile (capsu-
lar and vascular tumor invasion) were
reported; however, stringent criteria
for malignancy were not met.
Figure 3. Confocal Microscopy of HeLa Cells Transfected With c.280CT, p.Arg94Trp;
c.208GA, p.Asp70Asn; c.419GA, p.Cys140Tyr; c.418TC, p.Cys140Arg; and c.3GT,
p.Met1? Mutant or Wild-Type FP/TMEM127 Constructs
Wild-type  FP/TMEM127 protein
5 µm
Met1?
Asp70Asn Arg94Trp
Cys140Tyr Cys140Arg
Each construct expresses green fluorescent protein fused to the FP/TMEM127 sequence at the N terminus.
Cells were fixed and stained with 4,6-diamidino-2-phenylindole (nuclei) 24 hours after transfection. Green
fluorescent protein fluorescence was measured at 488 nm, as previously reported.14 Scale bar is indicated. The
5 mutant constructs have a diffuse cytoplasmic location in contrast with the wild-type protein, which is dis-
tributed in the plasma membrane and in discrete organelles within the cytoplasm.
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All tumors with FP/TMEM127
mutat ions were catecholamine
secreting, with no preferential pro-
duction of either norepinephrine or
epinephrine. Moreover, no recurrent
clinical manifestations other than
pheochromocytoma were detected in
the FP/TMEM127-mutated cases,
although other neoplasias were
reported in 3 of these patients
(Table 2).
Enforced expression of GFP fusion
constructs of 5 novel mutations in HeLa
cells revealed that these variants had a
subcellular distribution distinct from
that of wild-type FP/TMEM127, which
shows a typical plasma membrane and
punctate cytoplasmic localization pat-
tern corresponding to endomembrane
organelles (endosome, lysosome, and
Golgi body) (FIGURE 3 and eFigure 3).
The mutant proteins were localized dif-
fusely within the cytoplasm (Figure 3).
Similar results were obtained with 2 in-
dependent cell lines, HEK293T and
MPC9/30 (eFigure 3), indicating that
these effects were not cell-specific.
COMMENT
In this study, we assessed the preva-
lence of mutations of FP/TMEM127, a
recently identified pheochromocy-
toma susceptibility gene, in a large,
multi-institutional, ethnically diverse co-
hort of 990 individuals with pheochro-
mocytomas and paragangliomas
(Table 1). Overall, 19 mutations de-
tected in 20 independent families were
considered potentially pathogenic (2%)
based on a combination of sequence con-
servation data, prediction algorithms,
LOH, clinical segregation of the muta-
tion in families, and in vitro studies.
The main phenotypic associations
that could be drawn from our analysis
suggest the following pattern in asso-
ciation with FP/TMEM127: (1) muta-
tions were detected only in patients with
tumors of adrenal localization (pheo-
chromocytomas) but not with paragan-
gliomas; (2) age at onset of tumors in
patients with mutations was similar to
that of patients with sporadic disease;
(3) while combined bilateral and fa-
milial cases accounted for almost half
of the mutant cases, more than one-
third of the mutation carriers pre-
sented with a sporadic-appearing, be-
nign pheochromocytoma after age 40
years; (4) malignancy was rarely found
among FP/TMEM127 mutation carri-
ers; and (5) no recurrent pattern of
manifestations other than pheochro-
mocytoma was detected among the af-
fected individuals or families, al-
though the presence of other neoplastic
manifestations in a few patients, in-
cluding medullary carcinoma of the thy-
roid, supports the idea that clinical dis-
ease associated with FP/TMEM127
mutations may mimic other pheochro-
mocytoma-associated syndromes (eg,
multiple endocrine neoplasia type 2A).
A clear familial history of pheochro-
mocytoma was observed in only a quar-
ter of cases, suggesting low pen-
etrance of FP/TMEM127mutant alleles.
However, a comprehensive assess-
ment of age-related penetrance of
FP/TMEM127-associated disease was
not available in the current families and
awaits further analyses. The prelimi-
nary genotype-phenotype associa-
tions reported in the present study can
be used to further refine genetic test-
ing priorities in patients with pheo-
chromocytomas and suggest that
FP/TMEM127mutation screening may
be recommended for patients present-
ing at an older age with adrenal tu-
mors, especially but not exclusively
those with bilateral disease.
Loss of the wild-type FP/TMEM127
allele was detected in all informative
cases, suggesting a classic mechanism
of tumor suppressor gene inactivation
similar to other pheochromocytoma
susceptibility genes. However, in con-
trast with a minority of patients with
SDHB, SDHC, SDHD, or VHL gene de-
letions,4,5,22 our investigation of alter-
native mechanisms of primary gene dis-
ruption via germline deletions of the
entire gene or specific exons did not re-
veal any abnormalities in more than 500
samples tested. These results suggest
that small mutations are the main
mechanism of FP/TMEM127 disrup-
tion, although it cannot be excluded
that methylation of the gene pro-
moter, which has not yet been charac-
terized, can also occur in some cases.
Finally, the aberrant subcellular dis-
t r ibut ion of newly ident i f i ed
FP/TMEM127 mutations strongly sug-
gests that intracellular distribution
within the endomembrane system is rel-
evant for FP/TMEM127 function. Fu-
ture studies should determine quanti-
tative intracellular effects of individual
variants. We previously reported an
effect of FP/TMEM127 on mTOR
(mammalian target of rapamycin) sig-
nals.14 The mislocalization of mutated
proteins raises the possibility that
FP/TMEM127 might affect mTOR ac-
cessibility to its regulators and offers a
useful platform to test functions of
FP/TMEM127 in protein trafficking and
mTOR signaling in vitro.
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